Advertisement

Topics

BioRegio Rhein-Main Company Profile

18:25 EDT 25th September 2017 | BioPortfolio

Consultancy and technology transfer services for the University of Mainz. Emphasis placed on genomics, microbiology, genetic engineering, cellular biology and biochemistry.

Location

Duesbergweg 6
Mainz
D-55099
Germany

Contact

Phone: 49 61 31 39 52 00
Fax: 00 49 61 31 39 52 00


News Articles [198 Associated News Articles listed on BioPortfolio]

L’AFSSI ET EUROBIOMED MAIN DANS LA MAIN

Tous les jours un bref écho des principales infos de la veille avec le remindHIER de BiotechFinances Eurobiomed, le pôle de compétitivité santé PACA Languedoc-Roussillon et l’Afssi, l̵...

PATHWAY-2 uncovers main cause of drug-resistant hypertension, finds old drugs work best

Salt retention is the main culprit behind drug-resistant hypertension (RHTN), with older diuretic medications being the most effective treatment, according to new results from the PATHWAY-2 study.

Nasdaq Nordic: Nasdaq Stockholm Welcomes Saniona to the Main Market

Stockholm, June 15, 2017 - Nasdaq (Nasdaq: NDAQ) announced that Saniona AB (short name: SANION), a small cap company within the health care sector, has started trading of its shares on the main mar...

Gonorrhea Strains Across Europe Becoming More Susceptible to Main Treatment Options

A trend of decreasing cefixime resistance has been observed since 2010 across Europe: in 2015, cefixime resistance was detected in nine countries, compared to 10 in 2014 and 13 in 2013. Courtesy of EC...

Older men whose wives were main breadwinners suffered poorer health in later life

Men who came of age in the 1950s, and whose wives were their families' main breadwinners, were more likely than their contemporaries to suffer poor health in later life according to a study by Rutgers...

Insmed shares skyrocket after lung drug meets key study's main goal

(Reuters) - Shares of Insmed Inc more than doubled on Tuesday after the company said its drug to treat adults with a rare lung disorder met the main goal in a key study, leading it to apply for accele...

Alnylam's genetic disease drug meets main goal in key study

(Reuters) - Alnylam Pharmaceuticals Inc said on Wednesday its drug met the main goal in a late-stage study in patients suffering from a life-threatening genetic disease.

Arena's heart-lung drug meets main goal in mid-stage study

(Reuters) - U.S. drug developer Arena Pharmaceuticals Inc said on Monday its experimental drug for pulmonary arterial hypertension (PAH), a rare but deadly lung disease, met the main goal in a mid-sta...

PubMed Articles [417 Associated PubMed Articles listed on BioPortfolio]

Rhein ameliorates adenomyosis by inhibiting NF-κB and β-Catenin signaling pathway.

In the present study, we examined the effects of rhein on pituitary gland implantation-induced adenomyosis, an animal model which mimics human adenomyosis. Oral administration of rhein dose-dependentl...

Preparation, characterization, and in vivo study of Rhein Solid Lipid Nanoparticles for oral delivery.

In this study, rhein-SLNs were successfully produced by hot homogenization followed by ultrasonication. Precirol ATO5 in which Rhein exhibited higher partition coefficient was selected for preparation...

Neglect or good practice? Authors' reply to letters by Rhein and Degner.

Biodegradable nanoparticles for improved kidney bioavailability of rhein: preparation, characterization, plasma and kidney pharmacokinetics.

The aim of this work is to develop biodegradable nanoparticles for improved kidney bioavailability of rhein (RH). RH-loaded nanoparticles were prepared using an emulsification solvent evaporation meth...

Pharmacokinetics and pharmacodynamics of rhubarb anthraquinones extract in normal and disease rats.

Anthraquinones extract from Rheum palmatum L. (rhubarb) including rhein, emodin, aloe-emodin, chrysophanol, physcion and sennoside A, has been widely used in China to treat various diseases.

Clinical Trials [1359 Associated Clinical Trials listed on BioPortfolio]

Schlaganfallkonsortium Rhein-Neckar (Stroke Consortium Rhine-Neckar)

FAST is an investigator-initiated multicenter study embedded in a German multistate acute stroke network. The main objectives of the FAST study are to improve outcomes and quality of care ...

Genetic Basis of Odor Discrimination

Prior to the main study we will perform a pilot study on 60 subjects. The purpose of the pilot study is to identify the range of odor concentrations that will be used in the main study and...

Clinical Study to Evaluate the STENTYS Xposition S for Treatment of Unprotected Left Main Coronary Artery Disease

Prospective, non-randomized, multi-center study assessing the long term safety and efficacy of the self expandable sirolimus eluting Xposition S stent in the treatment of unprotected left ...

Randomized Comparison of Ultrasound Versus Radiofrequency Denervation in Patients With Therapy Resistant Hypertension

Prospective, randomized trial to assess the effectiveness of different renal sympathetic denervation methods (radiofrequency main vs. branches + main vs. ultrasound based) in a cohort of p...

Comparison of Coronary Wedge Pressure and Collateral Flow Index Between Main Branch and Side Branch Vessels

The purpose of this trial is to compare the degree of collateral flow in the main vessel and the side branch vessel. Specifically, the trial will address the superiority of the recruitable...

Companies [440 Associated Companies listed on BioPortfolio]

BioRegio Rhein-Main

Consultancy and technology transfer services for the University of Mainz. Emphasis placed on genomics, microbiology, genetic engineering, cellular biology and biochemistry.

BioRegio Jena e.V.,

The venerable Senate hall of the Alma Mater Jenensis can safely be called the cradle of our association BioRegio Jena e.V. It was here that in the late summer of 1995 about 15 to 20 biologists, physic...

Rhein Biotech N.V.

Rhein Biotech is a globally active biotech company and the world's third largest hepatitis B vaccine manufacturer. Berna Biotech, a fully integrated vaccine focused biotechnology company acquired 92.2...

BioCon Valley® GmbH

Born out of Germany´s "BioRegio" competition in 1996 BioCon Valley represents an interdisciplinary network in the field of modern life sciences and health care.Universities, research and health care ...

Main Drug Mart.

Mr. Souren Agemian, founder and president of Main Drug Mart, has laboured very diligently since 1968 to acquire the trust and confidence of his patients. As such, Main Drug Mart's reputation was quick...

More Information about "BioRegio Rhein-Main" on BioPortfolio

We have published hundreds of BioRegio Rhein-Main news stories on BioPortfolio along with dozens of BioRegio Rhein-Main Clinical Trials and PubMed Articles about BioRegio Rhein-Main for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioRegio Rhein-Main Companies in our database. You can also find out about relevant BioRegio Rhein-Main Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record